A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
NovoCure Ltd
NVCR
$2.0B
Mkt Cap
$17.65
-11.71%
NovoCure Ltd (NVCR) has a 5-year average return on invested capital (ROIC) of -17.7%. This is below average and may indicate limited pricing power.
NovoCure Ltd (NVCR) has a market capitalization of $2.0B. It is classified as a mid-cap stock.
NovoCure Ltd (NVCR) does not currently pay a regular dividend.
NovoCure Ltd (NVCR) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
NovoCure Ltd (NVCR) reported annual revenue of $655 million in its most recent fiscal year, based on SEC EDGAR filings.
NovoCure Ltd (NVCR) has a net profit margin of -20.8%. The company is currently unprofitable.
NovoCure Ltd (NVCR) generated $-76 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NovoCure Ltd operates in the Surgical & Medical Instruments & Apparatus industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 674M | 655M | 605M | 509M | 538M | 535M |
| Net Income | -173M | -136M | -169M | -207M | -93M | -58M |
| EPS | $-1.52 | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 |
| Free Cash Flow | -48M | -76M | -69M | -100M | 9.4M | 59M |
| ROIC | -153.8% | -27.4% | -24.3% | -21.4% | -9.3% | -6.2% |
| Gross Margin | 75.2% | 74.5% | 77.3% | 74.8% | 78.6% | 78.5% |
| Debt/Equity | 0.59 | 1.30 | 2.17 | 1.67 | 1.34 | 1.42 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -183M | -154M | -170M | -233M | -90M | -44M |
| Operating Margin | -27.2% | -23.5% | -28.2% | -45.7% | -16.6% | -8.3% |
| ROE | -52.3% | -38.9% | -46.7% | -51.5% | -21.7% | -13.2% |
| Shares Outstanding | 116M | 112M | 108M | 106M | 105M | 104M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | 83M | 177M | 248M | 351M | 494M | 535M | 538M | 509M | 605M | 655M | 674M |
| Gross Margin | N/A | N/A | 44.2% | 68.6% | 67.7% | 74.8% | 78.5% | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% | 75.2% |
| R&D | 40M | 44M | 41M | 38M | 51M | 79M | 132M | 201M | 206M | 223M | 210M | 225M | 229M |
| SG&A | 24M | 34M | 51M | 59M | 73M | 88M | 107M | 126M | 133M | 164M | 190M | 178M | 219M |
| EBIT | -80M | -104M | -115M | -39M | -34M | -914K | 30M | -44M | -90M | -233M | -170M | -154M | -183M |
| Op. Margin | N/A | N/A | -139.1% | -22.2% | -13.6% | -0.3% | 6.1% | -8.3% | -16.6% | -45.7% | -28.2% | -23.5% | -27.2% |
| Net Income | -81M | -112M | -132M | -62M | -64M | -7.2M | 20M | -58M | -93M | -207M | -169M | -136M | -173M |
| Net Margin | N/A | N/A | -159.1% | -34.8% | -25.6% | -2.1% | 4.0% | -10.9% | -17.2% | -40.6% | -27.9% | -20.8% | -25.7% |
| Non-Recurring | 330K | 402K | 6.9M | 747K | 933K | 1.2M | 1.6M | 2.1M | 955K | 6.7M | 3.2M | 4.9M | 4.9M |
| Returns on Capital | |||||||||||||
| ROIC | -50.6% | -60.0% | -51.5% | -27.4% | -26.9% | -2.4% | 48.3% | -6.2% | -9.3% | -21.4% | -24.3% | -27.4% | -153.8% |
| ROE | -59.8% | -64.0% | -67.1% | -48.2% | -56.3% | -4.4% | 5.7% | -13.2% | -21.7% | -51.5% | -46.7% | -38.9% | -52.3% |
| ROA | -136.8% | -52.5% | -44.7% | -22.5% | -21.0% | -1.8% | 2.6% | -5.3% | -7.9% | -17.7% | -14.1% | -13.3% | -22.0% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -74M | -100M | -108M | -33M | -1.9M | 27M | 99M | 83M | 31M | -73M | -26M | -49M | -27M |
| Free Cash Flow | -75M | -105M | -113M | -41M | -8.6M | 16M | 84M | 59M | 9.4M | -100M | -69M | -76M | -48M |
| Owner Earnings | -81M | -116M | -136M | -69M | -53M | -40M | 5.0M | -34M | -100M | -217M | -219M | -196M | -208M |
| CapEx | 849K | 4.7M | 5.7M | 7.4M | 6.7M | 10M | 15M | 24M | 21M | 27M | 43M | 27M | 21M |
| Maint. CapEx | 2.4M | 3.9M | 6.3M | 8.9M | 12M | 15M | 18M | 22M | 24M | 28M | 32M | 42M | 43M |
| Growth CapEx | 0 | 730K | 0 | 0 | 0 | 0 | 0 | 2.1M | 0 | 0 | 11M | 0 | 0 |
| D&A | 2.4M | 3.9M | 6.3M | 8.9M | 12M | 15M | 18M | 22M | 24M | 28M | 32M | 42M | 43M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 39.4% | 15.1% | 29.2% | 69.4% | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 4.6M | 12M | 22M | 27M | 40M | 52M | 76M | 95M | 107M | 116M | 160M | 105M | 138M |
| Debt Repayment | 0 | 0 | 0 | 76K | 100M | 31K | 150M | 26K | 28K | 10K | 13M | 561M | 561M |
| Balance Sheet | |||||||||||||
| Net Debt | -102M | -246M | -123M | -86M | -97M | -158M | -392M | -356M | -379M | -306M | -179M | -4.3M | -237M |
| Cash & Equiv. | 58M | 119M | 100M | 79M | 141M | 177M | 235M | 209M | 115M | 241M | 164M | 94M | 432M |
| Long-Term Debt | 0 | 23M | 96M | 97M | 149M | 149M | 430M | 562M | 566M | 569M | 97M | 195M | N/A |
| Debt/Equity | 0.00 | 0.09 | 0.68 | 0.86 | 1.33 | 0.77 | 0.95 | 1.42 | 1.34 | 1.67 | 2.17 | 1.30 | 0.59 |
| Interest Coverage | -279.3 | -32.1 | -15.8 | -3.4 | -2.0 | -0.1 | 1.7 | -5.0 | -11.0 | -47.5 | -14.6 | -6.9 | -6.9 |
| Equity | 98M | 251M | 142M | 114M | 112M | 218M | 477M | 410M | 441M | 362M | 360M | 340M | 331M |
| Total Assets | 118M | 307M | 282M | 265M | 340M | 479M | 1.1B | 1.1B | 1.2B | 1.1B | 1.2B | 804M | 788M |
| Total Liabilities | 20M | 57M | 140M | 152M | 228M | 262M | 575M | 729M | 750M | 784M | 881M | 464M | 457M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -277M | -388M | -520M | -582M | -644M | -651M | -631M | -686M | -778M | -986M | -1.2B | -1.3B | -1.4B |
| Working Capital | 94M | 265M | 225M | 195M | 257M | 354M | 886M | 931M | 953M | 855M | 350M | 424M | 414M |
| Current Assets | 112M | 294M | 262M | 245M | 321M | 440M | 999M | 1.1B | 1.1B | 1.0B | 1.1B | 647M | 632M |
| Current Liabilities | 18M | 29M | 37M | 50M | 65M | 86M | 114M | 143M | 159M | 179M | 756M | 223M | 218M |
| Per Share Data | |||||||||||||
| EPS | -6.46 | -1.33 | -1.54 | -0.70 | -0.69 | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | -1.56 | -1.22 | -1.52 |
| Owner EPS | -6.50 | -1.38 | -1.59 | -0.79 | -0.58 | -0.39 | 0.05 | -0.33 | -0.95 | -2.04 | -2.02 | -1.75 | -1.79 |
| Book Value | 7.84 | 2.99 | 1.66 | 1.29 | 1.22 | 2.11 | 4.33 | 3.94 | 4.20 | 3.41 | 3.33 | 3.05 | 2.86 |
| Cash Flow/Share | -5.94 | -1.19 | -1.26 | -0.38 | -0.02 | 0.26 | 0.90 | 0.79 | 0.29 | -0.69 | -0.24 | -0.44 | -1.13 |
| Dividends/Share | N/A | 0.00 | 0.00 | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 12.5M | 83.8M | 85.6M | 88.1M | 92.1M | 103.3M | 110.0M | 104.2M | 105.2M | 106.2M | 108.1M | 111.7M | 115.8M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 943.3 | N/A | N/A | N/A | N/A | N/A | -11.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | 560.5 | 222.0 | 143.1 | 774.8 | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | 601.0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 8.3 | 4.8 | 15.9 | 26.9 | 41.5 | 39.2 | 20.4 | 16.6 | 4.6 | 9.2 | 4.4 | 6.2 |
| Price/Sales | N/A | N/A | 11.5 | 7.3 | 11.7 | 19.0 | 19.9 | 29.6 | 14.8 | 9.6 | 3.2 | 2.8 | 3.0 |
| FCF Yield | N/A | -5.0% | -16.7% | -2.2% | -0.3% | 0.2% | 0.5% | 0.7% | 0.1% | -6.0% | -2.1% | -5.0% | -2.4% |
| Market Cap | N/A | 2.1B | 676M | 1.8B | 3.0B | 9.0B | 18.7B | 8.4B | 7.3B | 1.7B | 3.3B | 1.5B | 2.0B |
| Avg. Price | N/A | 23.89 | 11.15 | 14.69 | 31.39 | 64.72 | 89.57 | 152.01 | 75.65 | 46.28 | 17.83 | 16.63 | 17.65 |
| Year-End Price | N/A | 24.80 | 7.90 | 20.50 | 32.84 | 87.56 | 169.79 | 80.46 | 69.48 | 15.78 | 30.70 | 13.48 | 17.65 |
NovoCure Ltd passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 76.8%.
NovoCure Ltd (NVCR) has a debt-to-equity ratio of 1.30. This indicates moderate leverage.
NovoCure Ltd (NVCR) reported earnings per share (EPS) of $-1.22 in its most recent fiscal year.
NovoCure Ltd (NVCR) has a return on equity (ROE) of -38.9%. A negative ROE may indicate losses or negative equity.
NovoCure Ltd (NVCR) has a 5-year average gross margin of 76.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 13 years of financial data for NovoCure Ltd (NVCR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
NovoCure Ltd (NVCR) has a book value per share of $3.05, based on its most recent annual SEC filing.